Isis gets $3.5M as antisense drug trial proceeds

05/12/2013 | Genetic Engineering & Biotechnology News

Biogen Idec paid Isis Pharmaceuticals a $3.5 million milestone fee after the dosing of the first infant with spinal muscular atrophy in a midstage trial of the antisense drug ISIS-SMN. The open-label study, which will involve eight infants with the condition, will be carried out in the U.S. and Canada.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations